Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects
Status:
Completed
Trial end date:
2017-10-13
Target enrollment:
Participant gender:
Summary
AZD8871 is a new chemical entity possessing long-acting dual-pharmacology (muscarinic
receptor antagonist and β2 adrenoceptor agonist [MABA]) in a single molecule. This type of
agent presents a novel approach to the treatment of chronic obstructive pulmonary disease
(COPD) and potentially asthma (in combination with an inhaled corticosteroid). AZD8871 is
being developed for inhalation, formulated with alpha lactose monohydrate and delivered by
dry powder inhaler (DPI) that allows delivery of a single dose of the study drug.
The primary objective is to investigate the safety and tolerability of AZD8871 at steady
state in healthy male Japanese subjects.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Collaborators:
Covance Industrias Farmacéuticas Almirall S.A. Parexel The Doctors Laboratory